Reports
Sale
Global Oncology Drugs Market Size, Share, Growth, Trends, Analysis, Forecast: By Drug Class: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others; By Indications: Lung Cancer, Stomach Cancer, Others; By Route of Administration; By End User; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031
Global Oncology Drugs Market Outlook
The oncology drugs market size attained a value of USD 156.7 billion in 2022. The market is anticipated to grow at a CAGR of 7.3% during the forecast period of 2023-2031 to attain a value of USD 295.5 billion by 2031.
Global Oncology Drugs Market Trends
Oncology is a branch of science that focuses on the study of tumours and cancers. The studies are conducted to develop treatment, diagnosis, and prevention methods for cancer. The treatment methods include medical oncology, radiation oncology, and surgical oncology, among other drugs. Oncology drugs are specific medicines that are manufactured and utilized to target tumour cells.
- The deteriorating lifestyle and poor diets of people due to the hectic lifestyles are some of the largest contributors to the rise in cancer cases. The rising prevalence of cancer cases around the world is one of the primary factors propelling the oncology market development as patients continue to seek treatment.
- Key companies and government agencies are making rapid development in the treatment of cancer. Increased investments are being made in the research and development of immunotherapy as a cancer treatment method and improving its efficiency, which can significantly enhance the market value.
- Key market players and healthcare institutes are increasing their efforts in introducing innovative cancer treatments and simultaneously raising awareness for the available treatments in the market. With the rising awareness among people, patients are increasingly opting for treatment, which in turn, will increase the demand for certain treatment methods.
Global Oncology Drugs Market Analysis
Based on drug class, the market can be segmented into cytotoxic drugs, hormonal drugs, and targeted drugs, among others. Based on therapy, the market can be bifurcated into immunotherapy, chemotherapy, and targeted therapy. Based on indication, the market can be divided into stomach cancer, colorectal cancer, prostate cancer, lung cancer, breast cancer, skin cancer, and bladder cancer, among others.
Based on dosage form, the market can be segmented into solids, liquids, and injectables. Based on distribution channels, the market bifurcations include retail pharmacies, online pharmacies, and hospital pharmacies, among others. The regional markets can be divided into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following oncology drugs market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
- Abbvie Inc.
- Amgen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Others
Drug Classes for Oncology Available in the Market
The market, based on drug class, can be categorised into cytotoxic drugs, targeted drugs, and hormonal drugs, among others. The targeted drug segment is expected to hold a dominant position in the market owing to the various advantages it provides during treatment procedures.
The treatment is directly focused on the disease and it allows to minimise side-effects that affect the normal cells in the surroundings. Due to such characteristics, the market demand for targeted drugs is constantly rising.
Different Therapies in the Oncology Drugs Market
Based on therapy, the market can be bifurcated into immunotherapy, chemotherapy, and targeted therapy. Among these segments, the targeted therapy segment will hold a significant position in the market owing to the rising awareness about targeted therapies in developing regions.
With the increasing prevalence of cancer cases, the market for targeted therapies is expected to expand further owing to its ability to specifically target the cancerous cells and treat certain types of metastatic cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Abbvie Inc. is a biopharmaceutical manufacturing company, founded in 2013 after separating from Abbott. The company works in the healthcare industry with an interest to develop innovative medicines and products that are capable of solving chronic diseases and enhancing lives.
The company is headquartered in Illinois, United States, and operates in different therapeutic focus areas, such as immunology, oncology, neuroscience, virology, eye care, women’s health, and gastroenterology.
Amgen, Inc. is a multinational biopharmaceutical company, pioneering the science of using living cells to make biological medicines. The company was founded in 1980 and specialises in biologics, human therapeutics, and the development of novel products for the treatment of complex diseases. The company utilises its expertise to develop innovations that can enable treatment solutions to improve peoples’ life. They have expanded their presence in over 100 countries and provide their products through various brands, including Aimovig, Avsola, Epogen, Evenity, and Corlanor, among others.
AstraZeneca plc. is a British-Swedish multinational pharmaceutical and biotechnology company, founded in 1999. The company is headquartered in Cambridge, United Kingdom, and is actively operating to introduce innovative and effective medicines. Their operations span more than 100 countries with a focus on manufacturing medicines in different fields, including oncology, cardiovascular and metabolic disease (CVMD), and respiratory. The company is also selectively active in areas of autoimmunity, neuroscience, and infection.
Other market players include F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc., and Novartis AG, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Indications |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Oncology Drugs Market Overview
6.1 Global Oncology Drugs Market Historical Value (2016-2022)
6.2 Global Oncology Drugs Market Forecast Value (2023-2031)
7 Global Oncology Drugs Market Landscape
7.1 Global Oncology Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Oncology Drugs Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by End User
7.2.3 Analysis by Indication
8 Oncology Drug Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Oncology Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Oncology Drugs Market Segmentation
11.1 Global Oncology Drugs Market by Drug Class
11.1.1 Market Overview
11.1.2 Chemotherapy
11.1.2.1 Alkylating Agents
11.1.2.2 Antimetabolites
11.1.2.3 Others
11.1.3 Targeted Therapy
11.1.3.1 Monoclonal Antibodies
11.1.3.2 Others
11.1.4 Immunotherapy
11.1.5 Hormonal Therapy
11.1.6 Others
11.2 Global Oncology Drugs Market by Indications
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Stomach Cancer
11.2.4 Colorectal Cancer
11.2.5 Breast Cancer
11.2.6 Prostate Cancer
11.2.7 Liver Cancer
11.2.8 Esophageal Cancer
11.2.9 Cervical Cancer
11.2.10 Kidney Cancer
11.2.11 Bladder Cancer
11.2.12 Others
11.3 Global Oncology Drugs Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.2.1 Tablets
11.3.2.2 Capsules
11.3.3 Parenteral
11.3.3.1 Intravascular
11.3.3.2 intramuscular
11.3.4 Others
11.4 Global Oncology Drugs Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Specialty Centers
11.4.5 Research Institutes
11.4.6 Others
11.5 Global Oncology Drugs Market by Distribution Channels
11.5.1 Market Overview
11.5.2 Hospitals Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Global Oncology Drugs Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Oncology Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Oncology Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Oncology Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Oncology Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Oncology Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Mylan N.V.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Teva Pharmaceutical Industries Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline plc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Bayer AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Eli Lilly and Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co., Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Allergan
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 AstraZeneca
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 AbbVie Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Johnson & Johnson Private Limited
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Cipla Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Abbott
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Merck KGaA
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 LEO Pharma A/S
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Bausch Health Companies Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Sun Pharmaceutical Industries Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Aurobindo Pharma
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
23.22 Lupin
23.22.1 Financial Analysis
23.22.2 Product Portfolio
23.22.3 Demographic Reach and Achievements
23.22.4 Mergers and Acquisitions
23.22.5 Certifications
23.23 Hikma Pharmaceuticals PLC
23.23.1 Financial Analysis
23.23.2 Product Portfolio
23.23.3 Demographic Reach and Achievements
23.23.4 Mergers and Acquisitions
23.23.5 Certifications
23.24 Fresenius Kabi AG
23.24.1 Financial Analysis
23.24.2 Product Portfolio
23.24.3 Demographic Reach and Achievements
23.24.4 Mergers and Acquisitions
23.24.5 Certifications
23.25 Amneal Pharmaceuticals LLC.
23.25.1 Financial Analysis
23.25.2 Product Portfolio
23.25.3 Demographic Reach and Achievements
23.25.4 Mergers and Acquisitions
23.25.5 Certifications
24 Global Oncology Drugs Market-Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global oncology drug market was valued at USD 156.7 billion in 2022.
The market is expected to grow at a CAGR of 7.3% from 2023 to 2031 to reach a value of USD 295.5 billion by 2031.
The poor food habits and lifestyle of people has propelled the rising number of cancer cases around the world. Along with that, the increasing research and development activities conducted for the launching of novel treatment products are the major drivers for market development.
The rising awareness among people about the treatment is a key trend which is bolstering the market growth. Moreover, market players and government agencies increasingly investing in the development of cancer treatment solutions are expected to deliver new growth opportunities to the market.
The regional markets include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The different classes of drugs include cytotoxic drugs, hormonal drugs, and targeted drugs, among others.
The oncology drug therapies include immunotherapy, chemotherapy, and targeted therapy.
The different indications in the market for oncology drugs include stomach cancer, colorectal cancer, prostate cancer, lung cancer, breast cancer, skin cancer, and bladder cancer, among others.
Various dosage forms used for oncology drugs include solids, liquids, and injectable.
The market utilizes various distribution channels such as retail pharmacies, online pharmacies, and hospital pharmacies, among others.
The key players in the market include Abbvie Inc., Amgen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc., and Novartis AG, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER